What is DLBCL? Diffuse large B-cell lymphoma is a fast-growing B-cell non-Hodgkin lymphoma. NCI definition. Tissue classification establishes the exact diagnosis and specialist care considers disease extent and health.
Confidence: moderate to high for selected diagnostic and safety distinctions. Treatment pathways are attributed clinical guidance; independent superiority of a medicine or supplement is not established by this review.
- Keep the full pathology name and genetic report.
- Protein expression and gene rearrangements are distinct findings.
- Prompt high-grade care is distinct from watch and wait for selected slow-growing lymphomas.
- PET findings may need confirmation.
Table of contents
- Evidence summary
- What adult DLBCL is: large cells, rapid growth and the NOS boundary
- Symptoms: an enlarging mass, sweats and disease away from lymph nodes
- Biopsy and pathology: adequate tissue before a treatment decision
- Cell-of-origin, double-expression and double-hit
- Staging and baseline assessment: extent, fitness and organ function
- Treatment: prompt specialist care with a clearly stated purpose
- Response and recurrence: a scan finding may need confirmation
- Treatment safety: infection, immune injury and tumor lysis
- Fertility, nutrition and supplements: practical care alongside treatment
- Follow-up and research limits: response is not the whole care plan
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Pathology | WHO; ICC | Publishing support and author ties. | Naming only. |
| Care | NCI PDQ; EHA 2025 | Connected authors; trial finance unclosed. | No efficacy ranking. |
| Safety | NHS; NCI tumor lysis | Public/gift routes; trial receipts unknown. | Clinician-led care. |
| Support and survivorship | NCI follow-up | Institutional and contributor funding kept separate. | Actual treatment exposures and individual plans matter. |
What adult DLBCL is: large cells, rapid growth and the NOS boundary
DLBCL is fast-growing B-cell lymphoma. “Large” describes its microscopic cells, not extent; nodes or organs may be involved. NCI definition.
DLBCL, NOS has large-cell appearance, mature B-cell characteristics and no criteria for another specific large B-cell entity. WHO boundary.
NOS is a recognized diagnosis, not shorthand for an uninvestigated lump.
This adult DLBCL, NOS guide does not complete separately classified large B-cell, childhood, transformed or genetically defined high-grade entities. Preserve the full diagnosis when looking for another guide.
Symptoms: an enlarging mass, sweats and disease away from lymph nodes
DLBCL can present with rapidly enlarging masses and local or systemic symptoms. NCI presentation.
Report the speed of change, but do not use it to establish a tissue diagnosis.
NHS lymphoma symptoms include a painless neck, armpit or groin lump, fever or shivering, night sweats, itching, breathlessness and unexplained weight loss. An urgent referral is an investigation, not proof of cancer. NHS symptom and referral context. Follow the referral rather than waiting to see whether a painless lump starts to hurt.
The absence of a visible node does not exclude a problem inside the body. Bring previous imaging and biopsy reports, explain which symptoms are new and record whether a mass is changing. Severe breathing difficulty or sudden confusion needs emergency help, not a wait for a lymphoma-clinic appointment. NHS emergency signs.
Biopsy and pathology: adequate tissue before a treatment decision
A biopsy is the main diagnostic investigation; subsequent scans, blood tests or marrow sampling address further questions. NHS investigation roles. A blood result or a scan report alone does not necessarily supply the actual lymphoma name.
NCI advises pathology consultation before biopsy for special tissue preparation and experienced hematopathology review. NCI specimen context.
The service should plan a useful sample, rather than leave classification questions unanswered after the procedure.
Keep the report’s diagnosis, immunophenotype and genetic findings together. A sample labeled “suspicious” or “insufficient” requires the responsible service’s next step rather than self-treatment. Specialist review should reconcile an outside specimen with the current report. Procedure preparation and any anticoagulant interruption come from the service performing the biopsy; this article supplies no home preparation schedule.
Cell-of-origin, double-expression and double-hit
WHO retains germinal-center and activated B-cell-like groupings, with limited clinical use outside trials. WHO cell-of-origin.
Keep cell-of-origin labels separate from stage and the full prescribing plan.
Protein expression, gene rearrangements and copy-number changes are distinct; extra copies do not substitute for double-hit rearrangements. ICC distinctions.
Protein staining does not establish double-hit disease.
MYC/BCL6 rearrangements without BCL2: WHO uses morphology for DLBCL, NOS or HGBL, NOS; ICC retains a provisional entity. WHO; ICC.
Keep the classification system: BCL2 rearrangement excludes that MYC/BCL6-only group.
Staging and baseline assessment: extent, fitness and organ function
Stage describes extent, while grade and type describe different disease properties. NHS explains that these findings help treatment planning. NHS stage versus type. A rapidly growing localized lymphoma and an extensive lymphoma are not the same description.
NCI risk assessment includes age, stage, daily functioning, LDH and organ involvement. NCI risk context.
Ask what the actual findings mean in your assessment; do not diagnose lymphoma from a blood value or interpret a prognostic score as certainty.
EHA includes baseline viral screening and cardiac assessment in selected treatment preparation. EHA baseline assessment.
Bring prior hepatitis results, heart diagnoses and current medicines. The team needs actual clinical information before choosing a plan; this guide gives no IPI cutoff, universal marrow requirement or personal scan timetable.
Treatment: prompt specialist care with a clearly stated purpose
Fast-growing NHL needs prompt treatment, according to NHS guidance. Its selected care families include chemotherapy, targeted medicines and radiotherapy. NHS high-grade care context. Watch and wait described for selected slow-growing lymphomas should not be transferred to DLBCL.
NCI describes combination systemic treatment and selected radiation use in DLBCL care. NCI care context.
The specialist plan should state its aim and why the proposed components fit the actual diagnosis. This attributed description does not rank individual regimens independently.
A combination name may hide several medicines with different purposes and harms. Obtain the actual names and schedule from the service. This review does not substitute a generic online lymphoma regimen, order treatments by brand, or give numbers of cycles. The underlying intervention trials have not all been financially cleared.
Response and recurrence: a scan finding may need confirmation
Residual PET uptake may need further assessment or biopsy; EHA recommends tissue confirmation before relapse treatment. EHA confirmation.
A bright area is not automatically confirmed viable DLBCL.
Refractory cancer does not respond to treatment; relapse is a return after improvement. NCI refractory definition; NCI relapse definition.
The evidence for either label belongs in the clinical discussion. Keep previous pathology, treatment, response and time since treatment together, rather than reducing the record to one current scan.
NHS describes selected transplant, immune and targeted further-treatment pathways. NHS further-care families.
Eligibility is assessed for the actual case; another patient’s experience is not a personal referral criterion. Explain any new tissue-classification question before the next plan.
Treatment safety: infection, immune injury and tumor lysis
Possible infection during cancer treatment requires prompt contact with the oncology team; fever-reducing medicines can hide a warning. NCI infection precautions. Use the service’s urgent plan, including after hours, rather than waiting for a scheduled infusion.
Tumor lysis occurs when rapidly dying cancer cells release contents into the blood, changing blood chemistry and potentially harming organs. NCI tumor-lysis definition. Assessment and prevention are clinician-led. Do not try to reproduce an online fluid or uric-acid medicine protocol at home.
Immunotherapy can inflame healthy tissues, with adverse effects during or after treatment. NCI immune-side-effect context. Report changes rather than assuming every symptom is simply the lymphoma. Emergency breathing difficulty, sudden confusion or a severe reaction needs immediate assessment. The urgent plan should identify the actual medicines and contact route; this guide gives no personal drug holds or home steroid treatment.
Fertility, nutrition and supplements: practical care alongside treatment
NCI’s female fertility and male fertility resources describe treatment-dependent fertility risks. Discuss future parenting before treatment where possible; preservation options require individual specialist assessment, not a universal guarantee.
Nutrition support is different from an anticancer diet claim. NCI separates dietary support from unproven cancer-treatment claims. NCI nutrition boundary. Problems eating or maintaining intake deserve practical help, not a restrictive diet chosen because lymphoma is fast-growing.
Food and supplement interactions depend on the anticancer medicine. NCI interaction context. Share labels for vitamins, herbs and products taken only between cycles. This review establishes no independent supplement control of DLBCL or relapse-prevention benefit. A product marketed for immunity does not thereby fit an immune or targeted cancer medicine safely.
Follow-up and research limits: response is not the whole care plan
NCI recommends a written treatment summary and follow-up plan after treatment. NCI survivorship planning. Keep drug and radiation details, major adverse effects and the current contact route so later clinicians can interpret new symptoms in the right context.
EHA discourages routine asymptomatic surveillance imaging, with selected exceptions. EHA follow-up.
A response scan and a scan ordered because symptoms changed serve different purposes. The individual service determines follow-up; no fixed interval or imaging ban is supplied here.
Dose, missed-dose, vomiting, pregnancy and adverse-effect instructions belong to the actual prescribing team. Emerging molecular categories, circulating DNA tests, laboratory mechanisms and animal findings do not automatically establish patient benefit. The evidence map preserves author interests and trial-finance gaps. Manufacturer efficacy is excluded from the independent verdict, and this adult guide does not complete each rare large B-cell entity.
Funding and source roles
Research funding at a glance
36 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: aggressive B-cell professional PDQ | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 3 connected reviewer chain, provisional; clinical context only. | C, provisional — 12 May 2025; aggressive B-cell scope only. Expert synthesis, not a formal guideline. |
| NHS: NHL symptoms | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL tests | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NHS: NHL treatment | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 10 March 2026; due March 2029. Simplification and source-study/contributor interests remain unclosed. |
| NCI: infection during cancer treatment | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 23 January 2020; dated safety context. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: immunotherapy side effects | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Reviewed 16 February 2023. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: female fertility | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: male fertility | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 14 May 2025. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: follow-up medical care | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 2 December 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: nutrition and cancer claims | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Posted 30 October 2024. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI: food and supplement interactions | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | B, provisional — public accountability and medical review favor accuracy; Updated 25 April 2024. Page and contributor receipts, and underlying-study finances, are unclosed. PDQ is an information summary, not a treatment guideline. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
| Greenspring Personal Oncology: Seifter service identity | Own page identifies Seifter as oncology lead and lists commercial insurers, Medicare and patient billing. Actual receipts and PDQ payments unknown. | United States; 2328 West Joppa Road, Lutherville, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own page. No audited income, manufacturer-payment or disease-page sponsor inferred. |
| WHO lymphoid classification, 2022 | Projekt DEAL open-access support; no interests declared. Separate later coauthor ties do not establish 2022 payments. | International; corresponding contacts UK, US and Germany. | Tier 3 known separately connected coauthor; taxonomy only. | C, provisional — 22 June 2022. Expert taxonomy; receipts unclosed; authorship correction below. |
| WHO classification authorship correction, 2023 | Original correction declares no competing interests; no separate production-money statement found. It corrects authors and affiliations. | International authors; corrected affiliations include Italy and Japan. | Tier 3 financially connected author group; record correction only. | C, provisional — 19 July 2023 full correction read. No treatment or classification outcome inferred from its authorship amendment. |
| Campo et al.: International Consensus Classification, 2022 | NCI/NIAID intramural support; CAC funding refers to 2016 financial record. Authors declare no competing financial interests; allocations unclosed. | International authors; corresponding contacts Barcelona, Spain, and Bethesda, United States. | Tier 3 financially connected funding chain; taxonomy only. | C, provisional — 15 September 2022 issue, online 2 June. Full 25-page original selected sections read; old project chain and supporting studies not cleared. |
| Swerdlow et al.: cited 2016 financial chain | Primary acknowledgments verify charitable/university and drug/test-company support for the Chicago CAC meeting, 31 March–1 April 2014, including Genentech, Incyte and Celgene. | International authors; historical meeting Chicago, United States. | Tier 4 manufacturer-supported historical project; finance only. | D for efficacy; C for historical financial trace — 19 May 2016. Complete primary author copy’s financial footer verified; direct publisher access failed. No inference of identical 2022 sponsors or receipts. |
| ICC erratum record, 2023 | PubMed record identifies the original ICC authors and January 2023 Figure 4 correction; no separate production-funding statement present. | United States; NLM index, Bethesda; original authors international. | Tier 3 administrative record, provisional. | C, provisional — 26 January 2023. Actual record/figure legend read; complete publisher correction body unavailable. No amended image or grading claim adopted. |
| DEAL: publication-payment mechanism | Own description: institutional publication/read fees replace subscription payments; agreements with commercial publishers. Not funding of clinical research itself. | Germany; DEAL Open Access Services, Landsberger Strasse 346, Munich. | Tier 3 institutional financial self-report. | C, provisional — undated body. Publishing access/cost remit favors traceable information; exact 2022 article payer and ledger remain unclosed. |
| ELN 2025: separately dated Hochhaus interests | ELN meeting support, no commercial production funding declared. Hochhaus: Enliven/Incyte/Novartis honoraria and institutional company research, including BMS and Pfizer. | International authors; Hochhaus affiliation Jena, Germany. | Tier 3 connected authors; financial record only. | C, provisional — 11 July 2025 original declarations read. Later relationships are not proof of money for the 2022 classification. |
| Sterling et al.: dated financial declaration, 2024 | Publisher declaration: Sterling had Jerome Greene Foundation support and Medical Logix/Haymarket consulting. Coauthor Paul’s patents/company ties are not assigned to Sterling. | United States; author affiliation Johns Hopkins, Baltimore; publisher MDPI, Switzerland. | Tier 3 known paid education-company consultant; finance only. | C, provisional — 15 October 2024 indexed original declarations read. Direct publisher 429/PMC challenge prevented full read. No inference of PDQ payment or current contracts. |
| Johns Hopkins: Sterling provider profile | Own profile identifies lymphoma care and lists insurer networks, including Aetna and Cigna. Exact clinical, research and PDQ receipts remain unknown. | United States; listed cancer-center location 401 North Broadway Street, Baltimore, Maryland. | Tier 4 provider promotion; identity only. | D for independent efficacy; C for identity — undated own profile. No audited income or personal manufacturer payments inferred; patient ratings excluded. |
| Medical Logix: separate sponsored education project | Own 14 November 2025 course identifies Regeneron educational grant and Medical Logix/Partners joint provision. Not evidence this donor paid Sterling or funded PDQ. | United States educational activity; company headquarters not established by this page. | Tier 4 manufacturer-supported education; finance only. | D for independent efficacy; C for financial self-report — exact project/date checked. Grant size, full company accounts and NHL allocation remain unclosed. |
| Haymarket: educational platform services | Own page markets client activity hosting, promotion, reporting and paid board-review courses. Specific clients, contracts and Sterling receipts unclosed. | Operator serves medical-education clients; exact headquarters not verified in this source. | Tier 4 commercial service promotion; finance only. | D for independent efficacy; C for financial route — undated own body read. Client-service incentives disclosed; engagement claims and clinical outcomes not adopted. |
| NCI dictionary: diffuse large B-cell lymphoma | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 context; trial finance unclosed. | C, provisional — undated short definition; contributor and study payments unclosed. |
| NCI dictionary: refractory cancer | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Undated actual definition; no personal treatment sequence. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI dictionary: relapse | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Undated actual definition; no numerical response threshold. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NCI dictionary: tumor lysis syndrome | Public appropriations and gifts are documented below; page/trial receipts unclosed. | United States; NCI. | Tier 2 clinical context, provisional; supporting trials not financially cleared. | C, provisional — public accountability and medical review favor accuracy; Undated actual short definition; no personal prevention protocol. Page and contributor receipts, and underlying-study finances, are unclosed. |
| NHS: emergency breathlessness | DHSC funding and national advertising policy documented below; page receipts unclosed. | United Kingdom; national NHS patient website, separate from provider trusts. | Tier 2 clinical context, provisional. | B, provisional — clinical accountability supports accuracy; Reviewed 30 January 2024; due January 2027. Simplification and source-study/contributor interests remain unclosed. |
| EHA large B-cell guideline, 2025 | No project funding declared. Thieblemont: Roche, AbbVie and Novartis honoraria; Davies: Roche and other company payments/institutional research. Further author ties disclosed. | European authors; EHA The Hague, Netherlands, separately traced. | Tier 3 commercially connected authors; guidance only. | C, provisional — 23 September 2025. Complete financial footer read; trial finance and receipts unclosed. |
| EHA: own annual report 2025 | Own report describes corporate/industry partnerships, activity sponsorship and reinvested congress/program proceeds. No full audited receipt ledger or disease-page allocation established. | Netherlands; EHA, The Hague, as separately documented in the official contact source. | Tier 3 institutional financial self-report. | C, provisional — 2025 report posted June 2026; actual 33-page report, selected finance page 32 read. Institutional mission does not erase commercial support or author ties. |
| EHA: current income and official contact disclosure | Own indexed body: membership/registration fees, charity and industry sponsorship, pharma grants and rented booths/symposia. Income figures refer to 2024; exact guideline receipts unclosed. | Netherlands; Koninginnegracht 12b, 2514 AA, The Hague. | Tier 3 institutional financial self-report. | C, provisional — 9 May 2025 page label. Complete indexed income/contact text read; direct access 403. No percentage, current audit assurance or trial independence inferred. |
| EHA large B-cell guideline correction, December 2025 | Correction to the commercially connected 2025 author group; no separate correction receipts identified. | European authors; separate EHA institutional trace below. | Tier 3 connected author group; administrative context. | C, provisional — 28 December 2025. Full original corrects CSF to cerebrospinal fluid and Marie José Kersten’s name; no outcomes adopted. |
Frequently asked questions
Is every large B-cell lymphoma DLBCL, NOS? No. NOS excludes other specific entities. WHO boundary. Keep the complete pathology name.
Does “large” mean advanced cancer? No. Microscopic cell appearance differs from disease extent.
Is double-expression the same as double-hit? No. Protein expression and rearrangements differ. ICC distinctions. Keep the actual report.
Can DLBCL use slow-growing lymphoma observation? Do not transfer that option. Follow prompt specialist high-grade care. NHS distinction.
Does positive PET prove relapse? Not automatically; tissue confirmation may be needed. EHA guidance. Contact the treating service.
Can supplements prevent recurrence? This review establishes no independent supplement relapse-prevention benefit. Discuss products with oncology for medicine-specific interaction review.
Sources and funding notes
Reviewed 4 October 2026. Adult DLBCL scope is bounded; rare large B-cell and childhood entities remain separate. Current professional PDQ leads Seifter and Sterling and their separately dated financial records were checked. EHA author interests remain disclosed; receipts unclosed. Historical 2014 CAC support was verified in the primary 2016 copy, without transfer to 2022. Numerical outcomes, personal scores/schedules, efficacy rankings and blanket pregnancy reassurance are excluded.
- NCI: aggressive B-cell professional PDQ — Presentation, specimen, risk and care-family context only.
- NHS: NHL symptoms — Symptoms and referral distinction.
- NHS: NHL tests — Biopsy and possible further investigations.
- NHS: NHL treatment — Selected treatment families and supervised observation.
- NCI: infection during cancer treatment — Urgent infection precautions only.
- NCI: immunotherapy side effects — Healthy-tissue inflammation and reporting only.
- NCI: female fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: male fertility — Pre-treatment fertility discussion, without preservation efficacy.
- NCI: follow-up medical care — Written follow-up plan and treatment record.
- NCI: nutrition and cancer claims — Nutrition versus unproven anticancer diets.
- NCI: food and supplement interactions — Medicine-specific interaction review only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
- Greenspring Personal Oncology: Seifter service identity — Named reviewer’s private-provider relationship only.
- WHO lymphoid classification, 2022 — Selected DLBCL, NOS, cell-of-origin and genetic naming only.
- WHO classification authorship correction, 2023 — Corrected author/institution record only.
- Campo et al.: International Consensus Classification, 2022 — Double-hit, double-expression and MYC/BCL6 naming distinctions only.
- Swerdlow et al.: cited 2016 financial chain — Historical funding trace only; no clinical findings.
- ICC erratum record, 2023 — Correction awareness; no figure-derived clinical claim.
- DEAL: publication-payment mechanism — Open-access payment route and operator identity only.
- ELN 2025: separately dated Hochhaus interests — WHO coauthor relationship only; no CML clinical claims.
- Sterling et al.: dated financial declaration, 2024 — Reviewer relationship only; no therapy findings.
- Johns Hopkins: Sterling provider profile — Named reviewer identity and provider relationship only.
- Medical Logix: separate sponsored education project — Consultant-company money route only; unrelated course.
- Haymarket: educational platform services — Consultant-company commercial-service route only.
- NCI dictionary: diffuse large B-cell lymphoma — Definition and large-cell versus disease-extent distinction.
- NCI dictionary: refractory cancer — Nonresponse definition only.
- NCI dictionary: relapse — Return after improvement definition only.
- NCI dictionary: tumor lysis syndrome — Cancer-cell breakdown and organ-harm description only.
- NHS: emergency breathlessness — Emergency severe breathing difficulty and sudden confusion.
- EHA large B-cell guideline, 2025 — Testing, relapse and follow-up context; no outcomes.
- EHA: own annual report 2025 — Institutional funding routes only; not guideline or trial allocation.
- EHA: current income and official contact disclosure — Institutional income channels and office identity only.
- EHA large B-cell guideline correction, December 2025 — Abbreviation and author-name correction only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.